David L Stern

US Patent:

6465422, Oct 15, 2002

Filed:

Apr 17, 1998

Appl. No.:

09/062365

Inventors:

Ann Marie Schmidt - Franklin Lakes NJ
David Stern - Great Neck NY

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

A21K 3718

US Classification:

514 2, 4241844, 4241851, 4241921, 435 691, 4353201, 435325, 530350, 530351, 530380, 536 231, 536 235, 536 234

Abstract:

The present invention provides for a method for inhibiting tumor invasion or metastasis in a subject which comprises administering to the subject a therapeutically effective amount of a form of soluble Receptor for Advanced Glycation Endproducts (RAGE). The present invention also provides a method for evaluating the ability of an agent to inhibit tumor invasion in a local cellular environment which comprises: (a) admixing with cell culture media an effective amount of the agent; (b) contacting a tumor cell in cell culture with the media from step (a); (c) determining the amount of spreading of the tumor cell culture, and (d) comparing the amount of spreading of the tumor cell culture determined in step (c) with the amount determined in the absence of the agent, thus evaluating the ability of the agent to inhibit tumor invasion in the local cellular environment. The present invention also provides a pharmaceutical composition which comprises a therapeutically effective amount of the agent evaluated in the aforementioned method and a pharmaceutically acceptable carrier.

US Patent:

6555340, Apr 29, 2003

Filed:

Mar 5, 1999

Appl. No.:

09/263312

Inventors:

Ann Marie Schmidt - Franklin Lakes NJ
David Stern - Great Neck NY

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

C12P 2106

US Classification:

435 691, 4353201, 435325, 536 235

Abstract:

The present invention provides for an isolated human EN-RAGE peptide. The present invention also provides for a method for determining whether a compound is capable of inhibiting the interaction of an EN-RAGE peptide with a RAGE peptide. The present invention also provides for a method for inhibiting inflammation in a subject which comprises administering to the subject a compound capable of interfering with the interaction between EN-RAGE peptide and receptor for advanced glycation endproduct (RAGE) in the subject thereby inhibiting inflammation in the subject.

US Patent:

6586750, Jul 1, 2003

Filed:

Aug 3, 2001

Appl. No.:

09/922492

Inventors:

Jean I. Montagu - Brookline MA
David Stern - Mountain View CA

Assignee:

Perlegen Sciences - Mountain View CA

International Classification:

G01N 2164

US Classification:

2504581, 2504591

Abstract:

An optical scanning system for examining material associated with a substrate includes at least one scanning module for displacing two or more objective lenses, at least one optical coupling system and a translation system. The two objective lenses are mounted on one or more scan arms and are constructed to scan over regions or subregions associated with the substrate. The scanning module is configured to displace the scan arm(s) to perform the scan and thereby displace the two objective lenses. Each objective lens is arranged to deliver light to the material and collect light from the material.

US Patent:

6670136, Dec 30, 2003

Filed:

Apr 5, 2001

Appl. No.:

09/826589

Inventors:

Ann Marie Schmidt - Franklin Lakes NJ
David Stern - Great Neck NY

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

G01N 3353

US Classification:

435 71, 530324, 530350, 5303881, 5303891

Abstract:

The present invention provides for an isolated human EN-RAGE peptide. The present invention also provides for a method for determining whether a compound is capable of inhibiting the interaction of an EN-RAGE peptide with a RAGE peptide, which comprises: (a) admixing: (i) a RAGE peptide or an sRAGE peptide or a fragment of either thereof, (ii) an EN-RAGE peptide or a fragment thereof, and (iii) the compound; (b) measuring the level of interaction between the peptide of step (a) (i) and the peptide of step (a) (ii), and (c) comparing the amount of interaction meausred in step (b) with the amount measured between the petpide of step (a)(i) and the peptide of step (a) (ii) in the absence of the compound, thereby determining whether the compound is capable of inhibiting the interaction of the EN-RAGE peptide with the RAGE peptide, wherein a reduction in the amount of interaction in the presence of the compound indicates that the compound is capable of inhibiting the interaction. The present invention also provides for a method for inhibiting inflammation in a subject which comprises administering to the subject a compound capable of interfering with the interaction between EN-RAGE peptide and receptor for advanced glycation endproduct (RAGE) in the subject thereby inhibiting inflammation in the subject.

US Patent:

6753150, Jun 22, 2004

Filed:

Oct 5, 1998

Appl. No.:

09/166649

Inventors:

Ann Marie Schmidt - Franklin Lakes NJ
David Stern - Great Neck NY

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

G01N 3353

US Classification:

435 71, 530350, 53038822, 5303873

Abstract:

The present invention provides a method for determining whether a compound is capable of inhibiting the interaction of a peptide with receptor for advanced glycation end product (RAGE), which comprises: (a) admixing: (i) the peptide, wherein amino groups of the peptide are inactivated by derivitization, (ii) RAGE or a fragment thereof, and (iii) the compound; (b) determining the amount of the peptide bound to RAGE or the fragment thereof, and (c) comparing the amount of bound peptide determined in step (b) with the amount determined when the peptide is admixed with RAGE or a fragment thereof in the absence of the compound, thereby determining whether the compound is capable of inhibiting the interaction of the peptide with RAGE or a fragment thereof, wherein a reduction in the amount of binding in the presence of the compound indicates that the compound is capable of inhibiting the interaction. The present invention also provides a method for inhibiting the interaction of an advanced glycation endproduct (AGE) with a receptor for advanced glycation endproduct (RAGE) in a subject which comprises administering to the subject a pharmaceutically acceptable amount of the compound identified in aforementioned screening method effective to inhibit the interaction between the AGE and the RAGE in the subject. The present invention also provides for a compound identified by the screening method and which is useful for the treatment of diabetes in a subject.

US Patent:

6781025, Aug 24, 2004

Filed:

Jul 11, 2001

Appl. No.:

09/903476

Inventors:

Ajit B Dandekar - South Plainfield NJ
Michael Hryniszak - Bordentown NJ
David Lawrence Stern - Annandale NJ
Jeffrey Scott Beck - Clinton NJ

Assignee:

ExxonMobil Chemical Patents Inc. - Houston TX

International Classification:

C07C 258

US Classification:

585467, 585904

Abstract:

The present invention provides a process for regenerating a spent aromatics alkylation or transalkylation catalyst comprising a molecular sieve by contacting the spent catalyst with an oxygen-containing gas at a temperature of about 120 to about 600Â C. and then contacting the catalyst with an aqueous medium, such as an ammonium nitrate solution, an ammonium carbonate solution or an acetic acid solution.

US Patent:

6878654, Apr 12, 2005

Filed:

Sep 13, 2002

Appl. No.:

10/243572

Inventors:

Ajit B. Dandekar - South Plainfield NJ, US
Michael Hryniszak - Bordentown NJ, US
Jeffrey S. Beck - Clinton NJ, US
David L. Stern - Annandale NJ, US
Kathleen M. Keville - Beaumont TX, US

Assignee:

ExxonMobil Chemical Patents Inc. - Houston TX

International Classification:

B01J020/34
B01J021/08

US Classification:

502 23, 502 26, 502 27, 502 28, 502 29, 502 33

Abstract:

The present invention provides a process for regenerating a spent aromatics alkylation or transalkylation catalyst comprising a molecular sieve by contacting the spent catalyst with an oxygen-containing gas at a temperature of about 120 to about 600 C. and then contacting the catalyst with an aqueous medium, such as an ammonium nitrate solution, an ammonium carbonate solution or an acid solution.

US Patent:

6888037, May 3, 2005

Filed:

Dec 13, 2002

Appl. No.:

10/319161

Inventors:

Ajit B. Dandekar - South Plainfield NJ, US
Michael Hryniszak - Bordentown NJ, US
David Lawrence Stern - Annandale NJ, US

Assignee:

ExxonMobil Chemical Patents Inc. - Houston TX

International Classification:

C07C002/66

US Classification:

585467, 585475, 585323

Abstract:

A process for producing cumene is provided which comprises the step of contacting benzene and propylene under at least partial liquid phase alkylating conditions with a particulate molecular sieve alkylation catalyst, wherein the particles of said alkylation catalyst have a surface to volume ratio of about 80 to less than 200 inch.